RxDoctor Payments Data

Joseph Spiegel, MD

Otolaryngology · Philadelphia, PANPI 1467472175

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Stryker at 35.3% of the total. That places this record below the midpoint for otolaryngology clinicians in PA, where the typical reported total is $881.

$73in general payments, 2019–2025

Across 4 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$26
  • GSK$24
  • Genentech USA, Inc.$24
$17,375in research payments, 2019–2025

Across 4 payments — averaging $4343.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$17K

What the payments were for

  • Food & beverage$73100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Stryker1$26
GSK2$24
Genentech USA, Inc.1$24

How this compares

$73 in reported general payments places this provider in the 10th percentile of 456 otolaryngology providers in Pennsylvania.

See all otolaryngology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$258,869
Medicare patients
535
Services billed
2,782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Famotidine510$7,910
Omeprazole370$4,620
Gabapentin184$3,005
Dexlansoprazole DrDexlansoprazole13$2,999
Ipratropium Bromide103$2,995
Arnuity ElliptaFluticasone Furoate20$2,761
Nortriptyline Hcl105$2,285
Pantoprazole Sodium106$2,164
Fluticasone Propionate123$2,095
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine22$1,278
Duloxetine Hcl44$1,171
Azelastine Hcl42$800
Azelastine-FluticasoneAzelastine/Fluticasone11$713
Propranolol Hcl13$623
Montelukast Sodium28$529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArnuity Ellipta$24$2,76120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 456 otolaryngology providers in Pennsylvania.

Other otolaryngology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →